Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study
Guidelines of the American Psychiatric Association for borderline personality disorder ( BPD ) indicate selective serotonin reuptake inhibitors and the serotonin and noradrenaline reuptake inhibitor ( SNRI ) venlafaxine for treating affective dysregulation and impulsive behavioural dyscontrol symptoms . The SNRI duloxetine has been studied in patients with major depression , generalized anxiety disorder and fibromyalgia , showing particular efficacy on somatic complaints . This study investigates duloxetine in the treatment of patients with BPD . Eighteen out patients with a DSM-IV-TR diagnosis of BPD were treated with open-label duloxetine , 60 mg/day , for 12 weeks . Patients were assessed at baseline , week 4 and 12 with the CGI Severity item , the BPRS , the HAM-D , the HAM-A , the SOFAS , the BPD Severity Index ( BPDSI ) and the HSCL-90-Somatization Subscale ( HSCL-90 SOM ) . Adverse effects were evaluated using the Dosage Record Treatment Emergent Symptom Scale . Statistics were performed with the analysis of variance . Significant P values were ≤0.05 . Fourteen patients completed the study . Four patients ( 22.2 % ) discontinued treatment in the first 4 weeks because of non-compliance . A significant change was found for : BPRS , HAM-D , SOFAS , BPDSI total score and items ‘ impulsivity ’ , ‘ outbursts of anger ’ and ‘ affective instability ’ and HSCL-90 SOM . Adverse effects were mild headache and nausea . Initial results suggest that duloxetine is an effective and well-tolerated treatment for BPD , with positive effects on somatic symptoms
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .